The Filing Desk

IRADIMED

IRMD · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

IRMD · Last close · November 13, 2026
$85.35
Value IRADIMED yourself

IRADIMED's revenue rose 14.4% to $84 million in fiscal 2025. Its operating margin was 31.2%, up from 30.0% a year earlier. Free cash flow was $17 million, down 2.5%. It paid out $15 million in dividends and buybacks, 88% of free cash flow. The diluted share count rose 0.6%.

IRADIMED CORPORATION Latest fiscal year ended December 31, 2025 10-K filed March 6, 2026 · 0001104659-26-024691 Updated
Revenue
$84M
14.4%
Operating margin
31.2%
1.2 pts
Net income
$22M
16.9%
Free cash flow
$17M
2.5%
Return on equity
24.8%
0.5 pts
Market cap
$1.1B
Nov 13 close
P/E
45.6x
On $1.87 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What IRADIMED does

IRadimed makes medical devices that are safe to use in the strong magnetic field of an MRI scanner, along with the accessories, disposable parts and services that go with them. It is based in Florida and makes its products at a single facility there.

Its main product is an intravenous (IV) infusion pump system that delivers anesthesia and other fluids during MRI scans. Ordinary pumps contain magnetic and electronic parts that can interfere with an MRI or be dangerous near its magnet. IRadimed says it is the only known provider of a non-magnetic IV pump system designed for MRI procedures. Its newest pump, the MRidium 3870, was introduced in 2025, and sales of the older 3860+ will stop during 2026. It also sells a patient vital signs monitor for use during MRI scans, and a remote display unit that lets staff control the pumps from outside the scanner room.

IRadimed makes money by selling pumps and monitors, and from the proprietary IV tubing sets that must be used with them, plus service. It sells to hospitals, acute care facilities and outpatient imaging centers in the United States and through distributors elsewhere. It says its markets are very competitive.

Its biggest risks, as it describes them

  • Depending on sales of its MRI-compatible IV pumps and vital signs monitors for most of its revenue.
  • Relying on a few outside suppliers for certain materials and components.
  • Making and storing all of its products at one facility in Florida.
  • Strict medical device rules, and competition in markets that it says are mature.
  • Depending on hospital buying groups and on distributors outside the United States.
From IRADIMED's annual report on Form 10-K, filed March 6, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 12.6% a year and net income 13.5% a year, as new shares raised the share count by 7% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments6258505251
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio11.2x9.1x4.7x8.8x8.0x
Quick ratio10.5x8.4x3.9x7.6x6.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project IRADIMED's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of IRADIMED reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 4032.2%35.8%34.9%
Altman Z''10.8615.7614.84
Accruals ratio4.2%−6.7%−2.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assets———
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put IRADIMED side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
IRADIMEDFY2514.4%31.2%20.5%———
Delcath SystemsFY25129.1%0.8%24.6%2.8%−101.4x6Compare
CeribellFY2536.1%−65.6%−46.7%———Compare
Kestra Medical TechnologiesFY2659.0%−141.6%−122.6%——4Compare
Butterfly NetworkFY2519.0%−88.5%−16.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue32233038324253667384
Revenue growth2.9%−29.0%31.9%26.5%−17.6%31.8%27.5%23.0%11.7%14.4%
Gross profit26182330243241505664
Research and development1221222333
Operating income11169−11016202226
Net income706101913171922
Diluted EPS (US$)0.600.040.520.780.110.741.021.351.501.75
Diluted shares (millions)12121212121313131313
Cash flow
Cash from operations9371061110142625
Capital expenditure1100001788
Free cash flow93710511961817
Dividends paid00000013131415
Share buybacks10200000000
Acquisitions0000000000
Stock-based compensation2222421223
Balance sheet at fiscal year end
Cash and short-term investments18182844506258505251
Debt incl. finance leases——————————
Total assets373948677183869298109
Total liabilities56611101112211214
Shareholders' equity32334256617274718795
Margins and ratios
Gross margin81.1%75.9%76.3%77.1%74.3%76.7%77.5%76.5%76.9%76.8%
Operating margin33.6%5.6%19.7%22.4%−2.4%23.5%29.3%30.6%30.0%31.2%
Net margin22.2%2.2%20.7%25.0%4.3%22.3%24.1%26.2%26.3%26.8%
Free cash flow margin26.5%11.4%23.5%25.6%16.9%25.8%17.3%9.2%24.1%20.5%
Rule of 40 (growth + FCF margin)29.4%−17.5%55.4%52.1%−0.7%57.6%44.8%32.2%35.8%34.9%
Return on capital——————————
Return on equity22.6%1.5%16.8%19.8%2.3%14.0%17.6%23.7%24.3%24.8%
Return on assets19.9%1.3%14.4%16.7%2.0%12.1%15.2%19.4%20.2%21.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: IRADIMED's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with IRADIMED.